pomalidomide
E854983
antineoplastic agent
immunomodulatory drug
orphan drug
pharmaceutical drug
small molecule
thalidomide analogue
Pomalidomide is an immunomodulatory drug used primarily to treat multiple myeloma, designed as a more potent and safer derivative of thalidomide.
All labels observed (1)
| Label | Occurrences |
|---|---|
| pomalidomide canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T10292221 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: pomalidomide Context triple: [thalidomide, relatedDrug, pomalidomide]
-
A.
bortezomib
Bortezomib is a proteasome inhibitor chemotherapy drug primarily used in the treatment of multiple myeloma and certain types of lymphoma.
-
B.
thalidomide
Thalidomide is an immunomodulatory drug historically known for causing severe birth defects, now used under strict controls to treat conditions such as multiple myeloma and complications of leprosy.
-
C.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
D.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
-
E.
Zaltrap
Zaltrap is a cancer medication (brand name for aflibercept) used primarily in combination chemotherapy to treat metastatic colorectal cancer by inhibiting vascular endothelial growth factor (VEGF).
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: pomalidomide Target entity description: Pomalidomide is an immunomodulatory drug used primarily to treat multiple myeloma, designed as a more potent and safer derivative of thalidomide.
-
A.
bortezomib
Bortezomib is a proteasome inhibitor chemotherapy drug primarily used in the treatment of multiple myeloma and certain types of lymphoma.
-
B.
thalidomide
Thalidomide is an immunomodulatory drug historically known for causing severe birth defects, now used under strict controls to treat conditions such as multiple myeloma and complications of leprosy.
-
C.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
D.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
-
E.
Zaltrap
Zaltrap is a cancer medication (brand name for aflibercept) used primarily in combination chemotherapy to treat metastatic colorectal cancer by inhibiting vascular endothelial growth factor (VEGF).
- F. None of above. chosen
Statements (79)
| Predicate | Object |
|---|---|
| instanceOf |
antineoplastic agent
ⓘ
immunomodulatory drug ⓘ orphan drug ⓘ pharmaceutical drug ⓘ small molecule ⓘ thalidomide analogue ⓘ |
| affectsPathway | ubiquitin–proteasome pathway ⓘ |
| belongsToClass |
IMiDs
NERFINISHED
ⓘ
immunomodulatory imide drugs ⓘ |
| decreasesCytokine | TNF-alpha ⓘ |
| developedAs |
more potent derivative of thalidomide
ⓘ
safer derivative of thalidomide ⓘ |
| hasAdverseEffect |
anemia
ⓘ
constipation ⓘ diarrhea ⓘ fatigue ⓘ increased risk of venous thromboembolism ⓘ neutropenia ⓘ peripheral neuropathy ⓘ thrombocytopenia ⓘ |
| hasATCCode | L04AX06 NERFINISHED ⓘ |
| hasBioavailability | high oral bioavailability ⓘ |
| hasBoxedWarningFor |
embryo-fetal toxicity
ⓘ
venous and arterial thromboembolism ⓘ |
| hasCASNumber | 19171-19-8 ⓘ |
| hasChemicalClass |
glutarimide derivative
ⓘ
phthalimide derivative ⓘ |
| hasChemicalFormula | C13H11N3O4 ⓘ |
| hasDosingSchedule | 21 days on, 7 days off per 28-day cycle ⓘ |
| hasEliminationHalfLife | approximately 7.5 hours ⓘ |
| hasEMAAuthorizationYear | 2013 ⓘ |
| hasFDAApprovalYear | 2013 ⓘ |
| hasIndication |
AIDS-related Kaposi sarcoma
ⓘ
Kaposi sarcoma in HIV-negative patients ⓘ refractory multiple myeloma ⓘ relapsed multiple myeloma ⓘ |
| hasIUPACName | 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione ⓘ |
| hasLegalStatusInEU | prescription only ⓘ |
| hasLegalStatusInUS | prescription only ⓘ |
| hasMechanismOfAction |
antiangiogenic activity
ⓘ
direct antitumor activity ⓘ immunomodulation ⓘ inhibition of cytokine production ⓘ |
| hasMolarMass | 273.24 g/mol ⓘ |
| hasPregnancyCategory | X (contraindicated in pregnancy) ⓘ |
| hasPregnancyPreventionRequirement | yes ⓘ |
| hasPrimaryIndication | multiple myeloma ⓘ |
| hasProteinBinding | 12–44% ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasStereochemistry | racemic mixture ⓘ |
| hasSynonym |
Actimid
NERFINISHED
ⓘ
CC-4047 NERFINISHED ⓘ |
| hasTradeName |
Imnovid
NERFINISHED
ⓘ
Pomalyst NERFINISHED ⓘ |
| hasTypicalDose | 4 mg once daily in 28-day cycles ⓘ |
| hasUNIID | 27O7W4T232 ⓘ |
| increasesCytokine |
interferon-gamma
ⓘ
interleukin-2 ⓘ |
| isAdministeredAs | oral capsule ⓘ |
| isChiral | yes ⓘ |
| isContraindicatedIn | pregnancy ⓘ |
| isDerivativeOf | thalidomide NERFINISHED ⓘ |
| isExcretedVia |
feces
ⓘ
urine ⓘ |
| isMetabolizedBy |
CYP1A2
NERFINISHED
ⓘ
CYP2C19 NERFINISHED ⓘ CYP3A4 NERFINISHED ⓘ |
| isSubjectTo | REMS program NERFINISHED ⓘ |
| isTeratogenic | true ⓘ |
| isUsedForPatients |
who have received at least two prior therapies for multiple myeloma
ⓘ
whose disease progressed on or within 60 days of completion of last therapy ⓘ |
| modulatesImmuneCells |
NK cells
ⓘ
T cells NERFINISHED ⓘ |
| molecularTarget | cereblon NERFINISHED ⓘ |
| requiresRiskManagementProgram | yes ⓘ |
| usedInCombinationWith | dexamethasone NERFINISHED ⓘ |
| wasApprovedBy |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| wasDevelopedBy | Celgene NERFINISHED ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: pomalidomide Description of subject: Pomalidomide is an immunomodulatory drug used primarily to treat multiple myeloma, designed as a more potent and safer derivative of thalidomide.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.